Percutaneous Biodegradable Biliary Stents for the Treatment of Benign Biliary Strictures.

Sponsor
Corporacion Parc Tauli (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05556668
Collaborator
Universitat Autonoma de Barcelona (Other)
50
1
2.4
20.8

Study Details

Study Description

Brief Summary

To assess safety and effectiveness in the long term of percutaneous insertion of Biodegradable (BD) Biliary Stents for the treatment of benign biliary strictures, in a single center experience.

Condition or Disease Intervention/Treatment Phase
  • Device: Percutaneous placement of biodegradable biliary stents

Detailed Description

This is an observational study (retrospective analysis on a prospective database) of patients that have been implanted a biodegradable stent in the biliary tree to treat benign stenosis.

From march 2011 until May 2020, a prospective collection of clinical data has been conducted in patients with symptomatic benign biliary strictures treated biodegradable polydioxanone stents. A strict follow-up protocol has been carried out according to standard practice (at 2, 4, 6 months and every 6 months up to 5 years). Once the follow-up is completed, the collected data will be analyzed, assessing the long term effectiveness and safety, but also other variables related to stent implantation and impact on patient's quality of life.

A subgroup analysis of anastomotic biliary strictures will be performed.

Study Design

Study Type:
Observational
Actual Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Role of Biodegradable Polydioxanone Biliary Stents for the Percutaneous Treatment of Benign Biliary Strictures.
Actual Study Start Date :
Aug 20, 2022
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Outcome Measures

Primary Outcome Measures

  1. Stent Primary Patency [Time from stent implantation to new intervention due to restenosis or occlusion detected by clinical signs and symptoms and confirmed by blood-test disturbances and/or imaging tests), assessed up to 60 months]

    Time until new intervention due to re-stenosis or occlusion (detected by clinical signs and symptoms and confirmed by blood-test disturbances and/or imaging tests)

  2. Adverse Events [From stent implantation to completion of follow-up, up to 5 years]

    Major and minor complications. The Clavien-Dindo classification will be used for grading the severity of complications.

Secondary Outcome Measures

  1. Technical Success [Immediate (during procedure)]

    To correctly deploy a biodegradable stent using a percutaneous approach covering the stricture with a residual stenosis of less than 30% of the lumen, and correct flow of contrast through it into the intestinal lumen

  2. Length of Hospital Stay [nights from admission to perform the stent implantation to discharge of the patient from the hospital, assessed up to 365 days]

    number of days that patients spend in hospital to have the stent inserted, including a 24-48h control cholangiogram

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patients over 18 years old attended in the interventional radiology department for the implantation of a biodegradable biliary stent (BBS: ELLA-CS, Hradec Kralove, Czech Republic), for each stenosis, by percutaneous technique.

  • Written informed consent given

Exclusion Criteria:
  • Patients under 18 years old

  • Patients with post-liver transplant biliary strictures

  • Patients for whom no post-intervention follow-up data are available

  • Patients in whom malignancy is demonstrated as a cause of the stricture after stent placement.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Parc Tauli Sabadell Sabadell Spain 08208

Sponsors and Collaborators

  • Corporacion Parc Tauli
  • Universitat Autonoma de Barcelona

Investigators

  • Principal Investigator: Eva Criado-Paredes, MD, CorporaciĆ³ Universitaria Parc Tauli

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eva Criado, Principal Investigator, Corporacion Parc Tauli
ClinicalTrials.gov Identifier:
NCT05556668
Other Study ID Numbers:
  • CSPT_ECP_2020_600
First Posted:
Sep 27, 2022
Last Update Posted:
Sep 27, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 27, 2022